343 related articles for article (PubMed ID: 28786099)
1. Current Landscape of Targeted Therapy in Lung Cancer.
Mayekar MK; Bivona TG
Clin Pharmacol Ther; 2017 Nov; 102(5):757-764. PubMed ID: 28786099
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapies for Lung Cancer.
Stinchcombe TE
Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
[TBL] [Abstract][Full Text] [Related]
3. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
5. Emerging targeted therapies in non-small cell lung cancer.
Khanal N; Ganti AK
Expert Rev Anticancer Ther; 2016; 16(2):177-87. PubMed ID: 26618563
[TBL] [Abstract][Full Text] [Related]
6. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
Oxnard GR
Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
8. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
[TBL] [Abstract][Full Text] [Related]
9. [Development of molecular targeted therapies in lung cancers].
Suda K; Mitsudomi T
Nihon Geka Gakkai Zasshi; 2014 May; 115(3):130-6. PubMed ID: 24946519
[TBL] [Abstract][Full Text] [Related]
10. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
11. Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
Wijesinghe P; Bollig-Fischer A
Adv Exp Med Biol; 2016; 890():1-23. PubMed ID: 26703796
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
13. [Personalized therapy of lung cancer - current standard and future challenges].
Riedel R; Wolf J
Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
[TBL] [Abstract][Full Text] [Related]
14. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.
Yoda S; Dagogo-Jack I; Hata AN
Pharmacol Ther; 2019 Jan; 193():20-30. PubMed ID: 30121320
[TBL] [Abstract][Full Text] [Related]
16. [Driver gene mutation and targeted therapy of lung cancer].
Mitsudomi T
Gan To Kagaku Ryoho; 2013 Mar; 40(3):285-90. PubMed ID: 23507588
[TBL] [Abstract][Full Text] [Related]
17. Current status of targeted therapy in non-small cell lung cancer.
Parums DV
Drugs Today (Barc); 2014 Jul; 50(7):503-25. PubMed ID: 25101332
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer.
Xie J; Zhang X
J Genet Genomics; 2016 Jan; 43(1):3-10. PubMed ID: 26842989
[TBL] [Abstract][Full Text] [Related]
19. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR in lung cancer: Lessons learned and future perspectives.
Steuer CE; Ramalingam SS
Mol Aspects Med; 2015 Nov; 45():67-73. PubMed ID: 26022942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
